Since Vical Incorporated (NASDAQ:VICL) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation of both companies.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Osmotica Pharmaceuticals plc||261.03M||0.56||110.99M||-4.56||0.00|
Table 1 demonstrates Vical Incorporated and Osmotica Pharmaceuticals plc’s gross revenue, earnings per share and valuation.
Table 2 provides us the return on equity, return on assets and net margins of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Osmotica Pharmaceuticals plc||-42.52%||0%||0%|
Vical Incorporated’s Current Ratio and Quick Ratio are 18.4 and 18.4 respectively. The Current Ratio and Quick Ratio of its competitor Osmotica Pharmaceuticals plc are 1.7 and 1.4 respectively. Vical Incorporated therefore has a better chance of paying off short and long-term obligations compared to Osmotica Pharmaceuticals plc.
Insider & Institutional Ownership
Roughly 38.6% of Vical Incorporated shares are held by institutional investors while 51.6% of Osmotica Pharmaceuticals plc are owned by institutional investors. Vical Incorporated’s share held by insiders are 0.97%. On the other hand, insiders held about 4.9% of Osmotica Pharmaceuticals plc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Osmotica Pharmaceuticals plc||-27.71%||-37.06%||-66.27%||-70.58%||0%||-67.35%|
For the past year Vical Incorporated’s stock price has smaller decline than Osmotica Pharmaceuticals plc.
Vical Incorporated beats on 6 of the 9 factors Osmotica Pharmaceuticals plc.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the companyÂ’s core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.